Hoofddorp, The Netherlands, 2 October 2019. IGEA Pharma N.V. (the “Company” and together with its subsidiaries “IGEA” or the “Group”) today announced that the collaboration with Diego Mortillaro is terminated. The former CEO resigned due to personal reasons. Diego Mortillaro remains one of the major shareholders of the Company with a look-up engagement until December 2019.

Continue reading →


Hoofddorp, the Netherlands, 14 July 2019. IGEA Pharma N.V. (the “Company” and together with its subsidiaries “IGEA” or the “Group”) today announced the launch of Alz1, the first solution designed to detect and reduce high free copper levels in the bloodstream – a risk factor associated with Alzheimer’s disease – through a first-of-its-kind in-home blood test and a dietary supplement for those with elevated free copper levels.

Continue reading →


Minutes of the first annual general meeting of IGEA Pharma N.V., a public limited liability company (naamloze vennootschap) incorporated under the laws of the Netherlands, having its corporate seat at Hoofddorp, the Netherlands (the “Company”), held on 6 June 2019 at 10:00 am CET at Hoofddorp Transpolis, Polarisavenue 1, 2123 JH Hoofddorp, the Netherlands (the “Meeting”).

Continue reading →




Dear Shareholder,

On behalf of IGEA Pharma N.V. (the “Company”), it is a pleasure to invite you to attend the Annual General Meeting on 6 June 2019 (the “AGM”). The meeting will be held at Hoofddorp Transpolis, Polarisavenue 1, 2123 JH Hoofddorp, the Netherlands. The meeting will start at 10.00 am. CET.

Continue reading →